CNS5:Astrocytoma, IDH-mutant - Revision history

Laveniya.Satgunaseelan: references inserted

2025-09-04T12:04:52Z

references inserted

← Older revision		Revision as of 07:04, 4 September 2025
Line 211:		Line 211:
	<br />		<br />
	\|-		\|-
	\|19q loss alone		\|19q loss alone
	\|N/A		\|N/A
	\|Rare		\|Rare
Line 218:		Line 218:
	\|Better outcome<ref>{{Cite journal\|last=Mirchia\|first=Kanish\|last2=Richardson\|first2=Timothy E.\|date=2020-07-06\|title=Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/32640746\|journal=Cancers\|volume=12\|issue=7\|pages=1817\|doi=10.3390/cancers12071817\|issn=2072-6694\|pmc=7408495\|pmid=32640746}}</ref>		\|Better outcome<ref>{{Cite journal\|last=Mirchia\|first=Kanish\|last2=Richardson\|first2=Timothy E.\|date=2020-07-06\|title=Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/32640746\|journal=Cancers\|volume=12\|issue=7\|pages=1817\|doi=10.3390/cancers12071817\|issn=2072-6694\|pmc=7408495\|pmid=32640746}}</ref>
	\|-		\|-
	\|Gains chr 7 and chr 8q		\|Gains chr 7 and chr 8q
	\|N/A		\|N/A
	\|Rare		\|Rare
Line 254:		Line 254:
	\|Oncogene		\|Oncogene
	<br />		<br />
	\|Common		\|Common
	\|D		\|D
	\|Yes (WHO CNS5)		\|Yes (WHO CNS5)
Line 263:		Line 263:
	\|Oncogene		\|Oncogene
	<br />		<br />
	\|Common		\|Common
	\|D		\|D
	\|Yes (WHO CNS5)		\|Yes (WHO CNS5)
Line 272:		Line 272:
	\|TSG		\|TSG
	<br />		<br />
	\|Common		\|Common
	\|D		\|D
	\|Yes (WHO CNS5)		\|Yes (WHO CNS5)
Line 291:		Line 291:
	\|D		\|D
	\|Yes (WHO CNS5)		\|Yes (WHO CNS5)
	\|Mutually exclusive with ATRX mutations<ref>{{Cite journal\|last=Cancer Genome Atlas Research Network\|last2=Brat\|first2=Daniel J.\|last3=Verhaak\|first3=Roel G. W.\|last4=Aldape\|first4=Kenneth D.\|last5=Yung\|first5=W. K. Alfred\|last6=Salama\|first6=Sofie R.\|last7=Cooper\|first7=Lee A. D.\|last8=Rheinbay\|first8=Esther\|last9=Miller\|first9=C. Ryan\|date=2015-06-25\|title=Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/26061751\|journal=The New England Journal of Medicine\|volume=372\|issue=26\|pages=2481–2498\|doi=10.1056/NEJMoa1402121\|issn=1533-4406\|pmc=4530011\|pmid=26061751}}</ref><ref>{{Cite journal\|last=Eckel-Passow\|first=Jeanette E.\|last2=Lachance\|first2=Daniel H.\|last3=Molinaro\|first3=Annette M.\|last4=Walsh\|first4=Kyle M.\|last5=Decker\|first5=Paul A.\|last6=Sicotte\|first6=Hugues\|last7=Pekmezci\|first7=Melike\|last8=Rice\|first8=Terri\|last9=Kosel\|first9=Matt L.\|date=2015-06-25\|title=Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors\|url=https://pubmed.ncbi.nlm.nih.gov/26061753\|journal=The New England Journal of Medicine\|volume=372\|issue=26\|pages=2499–2508\|doi=10.1056/NEJMoa1407279\|issn=1533-4406\|pmc=4489704\|pmid=26061753}}</ref><ref>{{Cite journal\|last=Killela\|first=Patrick J.\|last2=Reitman\|first2=Zachary J.\|last3=Jiao\|first3=Yuchen\|last4=Bettegowda\|first4=Chetan\|last5=Agrawal\|first5=Nishant\|last6=Diaz\|first6=Luis A.\|last7=Friedman\|first7=Allan H.\|last8=Friedman\|first8=Henry\|last9=Gallia\|first9=Gary L.\|date=2013-04-09\|title=TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal\|url=https://pubmed.ncbi.nlm.nih.gov/23530248\|journal=Proceedings of the National Academy of Sciences of the United States of America\|volume=110\|issue=15\|pages=6021–6026\|doi=10.1073/pnas.1303607110\|issn=1091-6490\|pmc=3625331\|pmid=23530248}}</ref>		\|Mutually exclusive with ATRX mutations<ref>{{Cite journal\|last=Cancer Genome Atlas Research Network\|last2=Brat\|first2=Daniel J.\|last3=Verhaak\|first3=Roel G. W.\|last4=Aldape\|first4=Kenneth D.\|last5=Yung\|first5=W. K. Alfred\|last6=Salama\|first6=Sofie R.\|last7=Cooper\|first7=Lee A. D.\|last8=Rheinbay\|first8=Esther\|last9=Miller\|first9=C. Ryan\|date=2015-06-25\|title=Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas\|url=https://pubmed.ncbi.nlm.nih.gov/26061751\|journal=The New England Journal of Medicine\|volume=372\|issue=26\|pages=2481–2498\|doi=10.1056/NEJMoa1402121\|issn=1533-4406\|pmc=4530011\|pmid=26061751}}</ref><ref>{{Cite journal\|last=Eckel-Passow\|first=Jeanette E.\|last2=Lachance\|first2=Daniel H.\|last3=Molinaro\|first3=Annette M.\|last4=Walsh\|first4=Kyle M.\|last5=Decker\|first5=Paul A.\|last6=Sicotte\|first6=Hugues\|last7=Pekmezci\|first7=Melike\|last8=Rice\|first8=Terri\|last9=Kosel\|first9=Matt L.\|date=2015-06-25\|title=Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors\|url=https://pubmed.ncbi.nlm.nih.gov/26061753\|journal=The New England Journal of Medicine\|volume=372\|issue=26\|pages=2499–2508\|doi=10.1056/NEJMoa1407279\|issn=1533-4406\|pmc=4489704\|pmid=26061753}}</ref><ref>{{Cite journal\|last=Killela\|first=Patrick J.\|last2=Reitman\|first2=Zachary J.\|last3=Jiao\|first3=Yuchen\|last4=Bettegowda\|first4=Chetan\|last5=Agrawal\|first5=Nishant\|last6=Diaz\|first6=Luis A.\|last7=Friedman\|first7=Allan H.\|last8=Friedman\|first8=Henry\|last9=Gallia\|first9=Gary L.\|date=2013-04-09\|title=TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal\|url=https://pubmed.ncbi.nlm.nih.gov/23530248\|journal=Proceedings of the National Academy of Sciences of the United States of America\|volume=110\|issue=15\|pages=6021–6026\|doi=10.1073/pnas.1303607110\|issn=1091-6490\|pmc=3625331\|pmid=23530248}}</ref>
	\|-		\|-
	\|''MET''		\|''MET''
Line 368:		Line 368:

	==References==		==References==
	~~(use the "Cite" icon at the top of the page)~~ <~~span style="color:#0070C0"~~>~~(''Instructions~~: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references. The reference list in this section will be automatically generated and sorted''</span><span style="color:~~#0070C0">''.''</span><span style="color~~:~~#0070C0">)~~</~~span~~>		<br />
			[[Category:CNS5]]
			[[Category:DISEASE]]
			[[Category:Diseases A]]
			<references />
	==Notes==		==Notes==
	<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.		<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.
Line 374:		Line 378:
	Prior Author(s):		Prior Author(s):
	<nowiki>*</nowiki>''Citation of this Page'': “Astrocytoma, IDH-mutant”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/CNS5:Astrocytoma, IDH-mutant</nowiki>.		<nowiki>*</nowiki>''Citation of this Page'': “Astrocytoma, IDH-mutant”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/CNS5:Astrocytoma, IDH-mutant</nowiki>.
	~~[[Category:CNS5]]~~
	~~[[Category:DISEASE]]~~
	~~[[Category:Diseases A]]~~
	~~<references />~~

Laveniya.Satgunaseelan: populated fields

2025-09-04T12:02:50Z

populated fields

Show changes

Laveniya.Satgunaseelan: populated fields

2025-09-04T10:37:09Z

populated fields

Show changes

Bailey.Glen at 17:31, 3 July 2025

2025-07-03T17:31:33Z

← Older revision		Revision as of 12:31, 3 July 2025
Line 29:		Line 29:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:51, 25 May 2025

2025-05-25T21:51:53Z

← Older revision		Revision as of 16:51, 25 May 2025
Line 118:		Line 118:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 173:		Line 173:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 206:		Line 206:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''

Bailey.Glen at 20:36, 25 May 2025

2025-05-25T20:36:32Z

← Older revision		Revision as of 15:36, 25 May 2025
Line 44:		Line 44:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Diffuse astrocytoma, IDH-mutant; anaplastic astrocytoma, IDH-mutant; glioblastoma, IDH-mutant; low-grade astrocytoma; lower-grade astrocytoma; high-grade astrocytoma; infiltrating astrocytoma; diffuse glioma
	\|}		\|}

Bailey.Glen at 19:36, 25 May 2025

2025-05-25T19:36:03Z

← Older revision		Revision as of 14:36, 25 May 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Astrocytoma, IDH-mutant}}		{{DISPLAYTITLE:Astrocytoma, IDH-mutant}}
	[[CNS5:Table_of_Contents\|Central Nervous System Tumours(WHO Classification, 5th ed.)]]		[[CNS5:Table_of_Contents\|Central Nervous System Tumours (WHO Classification, 5th ed.)]]

	{{Under Construction}}		{{Under Construction}}

Bailey.Glen at 17:51, 24 March 2025

2025-03-24T17:51:46Z

Show changes

Jennelleh: Jennelleh moved page Astrocytoma, IDH-Mutant to CNS5:Astrocytoma, IDH-mutant without leaving a redirect: Move to CNS5

2024-02-25T18:48:16Z

Jennelleh moved page Astrocytoma, IDH-Mutant to CNS5:Astrocytoma, IDH-mutant without leaving a redirect: Move to CNS5

← Older revision		Revision as of 13:48, 25 February 2024
(No difference)

Jennelleh at 17:19, 23 June 2023

2023-06-23T17:19:59Z

← Older revision		Revision as of 12:19, 23 June 2023
Line 1:		Line 1:
	==Primary Author(s)*==		==Primary Author(s)*==

	~~Riley Lochner, MD, University Hospitals/Case Western Reserve University~~		Put your text here

	~~Shashi Shetty, PhD, University Hospitals/Case Western Reserve University~~

	__TOC__		__TOC__